Hansoh Pharma in HK$3.9 Billion Share Placement

Cleary Gottlieb represented Hansoh Pharmaceutical Group Company Limited (03692.HK) (Hansoh Pharma) in a HK$3.9 billion (approximately $500 million) primary placement through the issuance of 108 million new shares.

Citigroup Global Markets Limited and Morgan Stanley Asia Limited acted as placing agents and overall coordinators in the placement.

The placing agreement was signed on August 20, 2025, and the placement closed on August 27, 2025.

Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China, focusing on major disease therapeutic areas such as oncology, anti-infectives, central nervous system, metabolism, and autoimmunity.